Anifrolumab, a relatively new monoclonal protein, is sparking considerable excitement within the scientific community as a viable therapy for various autoimmune disorders. This innovative agent targets the interferon receptor alpha chain, considerably blocking tissue damage that fuels the patholo

Visilizumab, a novel engineered antibody , exhibits a unique mode of action targeting selectively the siglec-9 receptor expressed on granulocytes . This interaction leads to a inhibition in granulocyte responsiveness, ultimately dampening inflammatory responses during acute tissue damage . The cl